3.80
+0.1(+2.70%)
Currency In USD
| Previous Close | 3.7 |
| Open | 3.72 |
| Day High | 3.81 |
| Day Low | 3.7 |
| 52-Week High | 14.2 |
| 52-Week Low | 2.64 |
| Volume | 61,430 |
| Average Volume | 165,375 |
| Market Cap | 55.69M |
| PE | 0.63 |
| EPS | 6 |
| Moving Average 50 Days | 3.88 |
| Moving Average 200 Days | 5.46 |
| Change | 0.1 |
If you invested $1000 in Veru Inc. (VERU) 10 years ago, it would be worth $231.71 as of October 01, 2025 at a share price of $3.8. Whereas If you bought $1000 worth of Veru Inc. (VERU) shares 5 years ago, it would be worth $147.86 as of October 01, 2025 at a share price of $3.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity
GlobeNewswire Inc.
Sep 23, 2025 12:30 PM GMT
MIAMI, FL, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced a suc
Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study
GlobeNewswire Inc.
Aug 11, 2025 12:30 PM GMT
MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced selection
Veru Announces Reverse Stock Split
GlobeNewswire Inc.
Aug 06, 2025 12:30 PM GMT
MIAMI, FL, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that i